<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>IND</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>FDA clears Qihan Biotech’s CAR T therapy QT-019C for clinic</title>
      <description>
        <![CDATA[Hangzhou Qihan Biotech Co. Ltd. has obtained IND clearance from the FDA for QT-019C, a universal allogeneic CAR T-cell therapy for autoimmune diseases. QT-019C cell injection is an off-the-shelf allogeneic CAR T-cell therapy engineered from healthy donor leukapheresis products to stably express two distinct CARs targeting CD19 and BCMA.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731233</guid>
      <pubDate>Thu, 21 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731233-fda-clears-qihan-biotechs-car-t-therapy-qt-019c-for-clinic</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Immune/Autoimmune-CAR-T-cell-therapy-rheumatoid-arthritis.webp?t=1766588083" type="image/jpeg" medium="image" fileSize="1074495">
        <media:title type="plain">Illustration of CAR T cell therapy in rheumatoid arthritis</media:title>
      </media:content>
    </item>
    <item>
      <title>Matter Bio files IND for Lm-LLO-TT for PDAC</title>
      <description>
        <![CDATA[Matter Bio has submitted its first IND application to the FDA for Lm-LLO-TT, the company’s lead therapeutic candidate, seeking to initiate a first-in-human phase I/IIa trial in patients with pancreatic ductal adenocarcinoma (PDAC).]]>
      </description>
      <guid>http://www.bioworld.com/articles/731179</guid>
      <pubDate>Wed, 20 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731179-matter-bio-files-ind-for-lm-llo-tt-for-pdac</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Endocrine/Pancreas1.webp?t=1712602217" type="image/jpeg" medium="image" fileSize="143528">
        <media:title type="plain">Pancreas</media:title>
      </media:content>
    </item>
    <item>
      <title>Mekanistic’s PI3K/EGFR inhibitor MTX-531 gains IND clearance </title>
      <description>
        <![CDATA[Mekanistic Therapeutics Inc. has obtained IND clearance from the FDA for MTX-531, the company’s lead oncology candidate. A phase I study will be conducted in patients with advanced solid tumors characterized by dysregulated EGFR and/or PI3K signaling, including head and neck and endometrial cancers. Dosing is expected to begin in the third quarter.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731175</guid>
      <pubDate>Wed, 20 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731175-mekanistics-pi3k-egfr-inhibitor-mtx-531-gains-ind-clearance</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Cancer-tumor-illustration.webp?t=1731081970" type="image/jpeg" medium="image" fileSize="313900">
        <media:title type="plain">Illustration of cancer tumor</media:title>
      </media:content>
    </item>
    <item>
      <title>MD Anderson gains IND nod for CD94-targeted CAR T therapy </title>
      <description>
        <![CDATA[The University of Texas MD Anderson Cancer Center has received IND clearance from the FDA to initiate a phase I trial of a novel CAR T-cell therapy, JV-394, for patients with relapsed or refractory CD94-positive T/natural killer (NK) cell lymphomas.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731141</guid>
      <pubDate>Mon, 18 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731141-md-anderson-gains-ind-nod-for-cd94-targeted-car-t-therapy</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-source/CAR-T-cell-attacking-a-cancer-cell.webp?t=1759242499" type="image/jpeg" medium="image" fileSize="874683">
        <media:title type="plain">Computer visualization of a CAR T cell attacking a cancer cell.</media:title>
        <media:description type="plain">Computer visualization of a CAR T cell attacking a cancer cell. Credit: C. Bock, CeMM.</media:description>
      </media:content>
    </item>
    <item>
      <title>KHN-921 gains IND clearance for &lt;em&gt;MYBPC3&lt;/em&gt;-associated HCM</title>
      <description>
        <![CDATA[Chengdu Origen Biotechnology Co. Ltd. and Vanotech Ltd. have announced IND clearance by the FDA for KHN-921 for the treatment of hypertrophic cardiomyopathy (HCM) associated with <em>MYBPC3</em> mutations.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731095</guid>
      <pubDate>Thu, 14 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731095-khn-921-gains-ind-clearance-for-emmybpc3-em-associated-hcm</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cardiovascular/Abstract-blue-human-heart-with-red-cardio-pulse-line-and-red-circle.webp?t=1752266610" type="image/png" medium="image" fileSize="259569">
        <media:title type="plain">Abstract blue human heart with red cardio pulse line and red circle</media:title>
      </media:content>
    </item>
    <item>
      <title>Mabwell’s 9MW5211 gains IND clearance for IBD </title>
      <description>
        <![CDATA[Mabwell (Shanghai) Bioscience Co. Ltd. has obtained IND clearance from the FDA for 9MW5211 for the treatment of inflammatory bowel disease (IBD). ]]>
      </description>
      <guid>http://www.bioworld.com/articles/730995</guid>
      <pubDate>Mon, 11 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730995-mabwells-9mw5211-gains-ind-clearance-for-ibd</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Gastrointestinal/Holographic-intestine.webp?t=1683669912" type="image/jpeg" medium="image" fileSize="171482">
        <media:title type="plain">Hands holding holographic intestine</media:title>
      </media:content>
    </item>
    <item>
      <title>FDA clears IND for Harbour Biomed’s HBM-7004</title>
      <description>
        <![CDATA[Harbour Biomed has gained IND clearance from the FDA for HBM-7004, enabling the initiation of a first-in-human phase I trial in subjects with advanced solid tumors. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/730950</guid>
      <pubDate>Fri, 08 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730950-fda-clears-ind-for-harbour-biomeds-hbm-7004</link>
    </item>
    <item>
      <title>Arrivent’s MUC16/NaPi2b-targeted ADC gains IND clearance</title>
      <description>
        <![CDATA[Arrivent Biopharma Inc. has obtained IND clearance from the FDA for ARR-002 (AV-P138-ADC), an antibody-drug conjugate (ADC) with an initial focus in ovarian and endometrial cancers and broader therapeutic potential across solid tumors. A phase I trial is expected to open in the second half of the year.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730948</guid>
      <pubDate>Fri, 08 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730948-arrivents-muc16-napi2b-targeted-adc-gains-ind-clearance</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Female-reproductive-system-and-cancer-cells.webp?t=1698266547" type="image/jpeg" medium="image" fileSize="414946">
        <media:title type="plain">Female reproductive system and cancer cells</media:title>
      </media:content>
    </item>
    <item>
      <title>Laguna Biotherapeutics’ LGNA-100 gains IND clearance</title>
      <description>
        <![CDATA[Laguna Biotherapeutics Inc. has obtained IND clearance from the FDA for its cancer immunotherapeutic LGNA-100 (QUAIL-100). The planned first-in-human phase I study will evaluate LGNA-100 in pediatric and young adult participants with high-risk acute leukemias and myelodysplastic syndromes following αβ-depleted hematopoietic stem cell transplantation (HSCT) to prevent leukemic relapse.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730792</guid>
      <pubDate>Thu, 30 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730792-laguna-biotherapeutics-lgna-100-gains-ind-clearance</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Leukemia.webp?t=1588713330" type="image/png" medium="image" fileSize="421137">
        <media:title type="plain">Leukemia illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Taiho and Araris announce IND clearance for ARC-02</title>
      <description>
        <![CDATA[Taiho Oncology Inc., Taiho Pharmaceutical Co. Ltd. and Araris Biotech AG have announced completion by the FDA of the IND review period for ARC-02, enabling initiation of a phase I trial by Taiho Oncology.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730721</guid>
      <pubDate>Tue, 28 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730721-taiho-and-araris-announce-ind-clearance-for-arc-02</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Non-Hodgkin-lymphoma-cells-in-the-blood-flow.webp?t=1642718747" type="image/png" medium="image" fileSize="492874">
        <media:title type="plain">Non-Hodgkin lymphoma cells in the blood flow</media:title>
      </media:content>
    </item>
    <item>
      <title>FDA clears IND for Naturecell’s Astrostem-AU for autism</title>
      <description>
        <![CDATA[Naturecell Co. Ltd.’s U.S. subsidiary, Naturecell America, has received IND clearance from the FDA for Astrostem-AU, an autologous adipose-derived mesenchymal stem cell therapy for adults with autism spectrum disorder (ASD).]]>
      </description>
      <guid>http://www.bioworld.com/articles/730431</guid>
      <pubDate>Thu, 16 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730431-fda-clears-ind-for-naturecells-astrostem-au-for-autism</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/Brain-clay-model.webp?t=1583439267" type="image/png" medium="image" fileSize="219558">
        <media:title type="plain">Brain clay model</media:title>
      </media:content>
    </item>
    <item>
      <title>‘Immune reset’ is ambition of Tr1x’s allogenic Tr1 cell therapy</title>
      <description>
        <![CDATA[Tr1x Inc. was founded with a simple but ambitious goal: to change how autoimmune and inflammatory diseases are treated,&nbsp;moving away from chronic treatment and toward durable cures. “We are trying to flip the script on regulatory T cells (Tregs),” Tr1x CEO David de Vries told <em>BioWorld</em>. “The goal is to reset the immune system rather than continuously suppress it, and we believe we have a unique technology to do that.”]]>
      </description>
      <guid>http://www.bioworld.com/articles/730296</guid>
      <pubDate>Tue, 14 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730296-immune-reset-is-ambition-of-tr1xs-allogenic-tr1-cell-therapy</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/Cell-therapy-illustration.webp?t=1758833925" type="image/jpeg" medium="image" fileSize="857445">
        <media:title type="plain">Cell therapy illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Canwell gains IND clearance for ADC CAN-016</title>
      <description>
        <![CDATA[Canwell Pharma Inc. has obtained IND approval from the FDA for CAN-016, a novel antibody-drug conjugate (ADC). The company will initiate a phase I study in patients with HER2-expressing solid tumors who have experienced disease progression following prior ADC therapies.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730166</guid>
      <pubDate>Tue, 07 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730166-canwell-gains-ind-clearance-for-adc-can-016</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Antibodies-research-discovery-immune.webp?t=1772641847" type="image/jpeg" medium="image" fileSize="240482">
        <media:title type="plain">Illustration of magnifying glass and antibodies</media:title>
      </media:content>
    </item>
    <item>
      <title>Telomir Pharmaceuticals submits IND in U.S. for Telomir-1 in TNBC</title>
      <description>
        <![CDATA[Telomir Pharmaceuticals Inc. has submitted an IND application to the U.S. FDA for its lead candidate, Telomir-1 (Telomir-Zn), for the treatment of advanced and metastatic triple-negative breast cancer (TNBC). Telomir-1 is a first-in-class metal-modulating epigenetic agent designed to restore transcriptional control in tumor cells by targeting intracellular iron-zinc homeostasis.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730058</guid>
      <pubDate>Wed, 01 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730058-telomir-pharmaceuticals-submits-ind-in-us-for-telomir-1-in-tnbc</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Dividing-breast-cancer-cell.webp?t=1733332699" type="image/jpeg" medium="image" fileSize="744395">
        <media:title type="plain">Illustration of dividing breast cancer cell</media:title>
      </media:content>
    </item>
    <item>
      <title>Otsuka to acquire PTSD drugmaker Transcend in $1.2B deal </title>
      <description>
        <![CDATA[Otsuka Pharmaceutical Co. Ltd. is taking a neuroplastogen approach to posttraumatic stress disorder (PTSD) through its planned $1.22 billion acquisition of Transcend Therapeutics Inc. The deal gives Tokyo-headquartered Otsuka access to Transcend’s lead asset, TSND-201, an oral neuroplastogen that has begun patient recruitment for a phase III study in the U.S.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730090</guid>
      <pubDate>Tue, 31 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730090-otsuka-to-acquire-ptsd-drugmaker-transcend-in-12b-deal</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Brain-with-handshake-and-cityscape.webp?t=1609792702" type="image/png" medium="image" fileSize="549630">
        <media:title type="plain">Brain with handshake and cityscape</media:title>
      </media:content>
    </item>
    <item>
      <title>Aktis Oncology’s AKY-2519 gains IND approvals</title>
      <description>
        <![CDATA[Aktis Oncology Inc. has obtained IND approvals from the FDA enabling the company to proceed to a phase Ib trial with AKY-2519, a miniprotein radioconjugate targeting B7-H3-expressing tumors, including prostate, lung and other solid tumors. Specifically, the IND clearances relate to [64Cu]Cu-AKY-2519 for imaging and [225Ac]Ac-AKY-2519 for therapeutic use.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730037</guid>
      <pubDate>Tue, 31 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730037-aktis-oncologys-aky-2519-gains-ind-approvals</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/theranostic-radiopharmaceutical-rendering.webp?t=1728421145" type="image/png" medium="image" fileSize="990505">
        <media:title type="plain">3D rendering conceptualizing theranostics</media:title>
      </media:content>
    </item>
    <item>
      <title>Otsuka to acquire PTSD drugmaker Transcend in $1.2B deal </title>
      <description>
        <![CDATA[Otsuka Pharmaceutical Co. Ltd. is taking a neuroplastogen approach to posttraumatic stress disorder (PTSD) through its planned $1.22 billion acquisition of Transcend Therapeutics Inc. The deal gives Tokyo-headquartered Otsuka access to Transcend’s lead asset, TSND-201, an oral neuroplastogen that has begun patient recruitment for a phase III study in the U.S.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729952</guid>
      <pubDate>Mon, 30 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729952-otsuka-to-acquire-ptsd-drugmaker-transcend-in-12b-deal</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Brain-with-handshake-and-cityscape.webp?t=1609792702" type="image/png" medium="image" fileSize="549630">
        <media:title type="plain">Brain with handshake and cityscape</media:title>
      </media:content>
    </item>
    <item>
      <title>Endocyclic’s ENDO-205 gains IND clearance for endometriosis</title>
      <description>
        <![CDATA[Endomet Biosciences Inc. (dba Endocyclic Therapeutics) has obtained IND clearance from the FDA for its lead program, ENDO-205, a first-in-class, nonhormonal targeted peptide therapeutic for endometriosis. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/729860</guid>
      <pubDate>Tue, 24 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729860-endocyclics-endo-205-gains-ind-clearance-for-endometriosis</link>
    </item>
    <item>
      <title>Innorna’s IN-026 gains IND clearance for refractory gout</title>
      <description>
        <![CDATA[Innorna Co. Ltd. has obtained IND clearance from the FDA for IN-026, enabling the company to initiate a phase I study of this mRNA-based therapy for refractory gout.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729689</guid>
      <pubDate>Wed, 18 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729689-innornas-in-026-gains-ind-clearance-for-refractory-gout</link>
    </item>
    <item>
      <title>Unixell Biotech’s UX-GIP001 gains IND clearance for epilepsy</title>
      <description>
        <![CDATA[Shanghai Unixell Biotechnology Co. Ltd. has obtained IND clearance from the FDA for UX-GIP001, its iPSC-derived allogeneic cell therapy for focal epilepsy. A phase I study will evaluate UX-GIP001 in patients with drug-resistant epilepsy.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729645</guid>
      <pubDate>Mon, 16 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729645-unixell-biotechs-ux-gip001-gains-ind-clearance-for-epilepsy</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/Epilepsy-illustration.webp?t=1600196724" type="image/png" medium="image" fileSize="542753">
        <media:title type="plain">Brain and encephalography</media:title>
      </media:content>
    </item>
    <item>
      <title>Rapport’s RAP-219 gets more phase III funding with Tenacia deal</title>
      <description>
        <![CDATA[Rapport Therapeutics Inc. added $20 million to its cash runway for its lead phase III oral seizure drug, RAP-219, through a potential $328 million license deal signed with Tenacia Biotechnology Co. Ltd.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729456</guid>
      <pubDate>Tue, 10 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729456-rapports-rap-219-gets-more-phase-iii-funding-with-tenacia-deal</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Brain-with-handshake-and-cityscape.webp?t=1609792702" type="image/png" medium="image" fileSize="549630">
        <media:title type="plain">Brain with handshake and cityscape</media:title>
      </media:content>
    </item>
    <item>
      <title>FDA clears IND for epigenetic immunoactivator</title>
      <description>
        <![CDATA[Great Novel Therapeutics Biotech & Medicals Corp.’s epigenetic immunoactivator, GNTbm-38, has received IND clearance from the FDA, enabling initiation of a phase I trial in the U.S.&nbsp;]]>
      </description>
      <guid>http://www.bioworld.com/articles/729392</guid>
      <pubDate>Fri, 06 Mar 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729392-fda-clears-ind-for-epigenetic-immunoactivator</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/TME-tumor-microenvironment-3D.webp?t=1699370810" type="image/jpeg" medium="image" fileSize="457538">
        <media:title type="plain">3D Rendering of tumor microenvironment</media:title>
      </media:content>
    </item>
    <item>
      <title>Kestrel’s KST-6051 gains IND clearance for KRAS-driven cancers</title>
      <description>
        <![CDATA[Kestrel Therapeutics Inc. has obtained IND approval from the FDA for KST-6051, an oral, small-molecule pan-KRAS inhibitor being developed for the treatment of KRAS-driven cancers.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729389</guid>
      <pubDate>Fri, 06 Mar 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729389-kestrels-kst-6051-gains-ind-clearance-for-kras-driven-cancers</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/NIH-KRAS-driven-lung-cancer.webp?t=1691416811" type="image/png" medium="image" fileSize="2538223">
        <media:title type="plain">Lung cancer driven by the Kras oncogene shown in purple</media:title>
        <media:description type="plain">Mutated KRAS-driven lung cancer cells (purple) in a genetically engineered mouse model of lung cancer. Credit: Eric Snyder, Huntsman Cancer Institute at the University of Utah/National Cancer Institute, NIH</media:description>
      </media:content>
    </item>
    <item>
      <title>UCB inks $1.1B deal for Antengene’s autoimmune bispecific TCE</title>
      <description>
        <![CDATA[Belgian pharma giant UCB SA is putting skin in the bispecific T-cell engager (TCE) game, announcing a potential $1.1 billion deal to license Antengene Corp.’s ATG-201. ATG-201 is a CD19/CD3 bispecific TCE antibody aimed at autoimmune disorders, though specific indications were not disclosed.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729298</guid>
      <pubDate>Wed, 04 Mar 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729298-ucb-inks-11b-deal-for-antengenes-autoimmune-bispecific-tce</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/Red-and-blue-bispecific-antibodies.webp?t=1765991281" type="image/jpeg" medium="image" fileSize="372546">
        <media:title type="plain">Red and blue bispecific antibodies</media:title>
      </media:content>
    </item>
    <item>
      <title>Systimmune’s iza-bren hits phase III breast cancer goals in China</title>
      <description>
        <![CDATA[In a boon for licensee Bristol Myers Squibb Co., Systimmune Inc.’s next-generation cancer drug, izalontamab brengitecan (iza-bren), hit both progression-free survival and overall survival endpoints in a phase III trial of Chinese patients with advanced triple-negative breast cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729321</guid>
      <pubDate>Tue, 03 Mar 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729321-systimmunes-iza-bren-hits-phase-iii-breast-cancer-goals-in-china</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/breast-cancer-wireframe.webp?t=1706887459" type="image/jpeg" medium="image" fileSize="349651">
        <media:title type="plain">Cancer tumor in breast illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Sanaregen Vision’s SVT-001 cleared for clinic for familial drusen</title>
      <description>
        <![CDATA[Sanaregen Vision Therapeutics Inc. has received FDA clearance to conduct a phase I/II trial of SVT-001, an investigational cell therapy for individuals with familial drusen.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729151</guid>
      <pubDate>Tue, 03 Mar 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729151-sanaregen-visions-svt-001-cleared-for-clinic-for-familial-drusen</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Ocular/Eye-macula-diagram.webp?t=1713453488" type="image/jpeg" medium="image" fileSize="294587">
        <media:title type="plain">Medical vector illustration showing cross section of an eyeball with close up of the macula</media:title>
      </media:content>
    </item>
    <item>
      <title>Systimmune’s iza-bren hits phase III breast cancer goals in China</title>
      <description>
        <![CDATA[In a boon for licensee Bristol Myers Squibb Co., Systimmune Inc.’s next-generation cancer drug, izalontamab brengitecan (iza-bren), hit both progression-free survival and overall survival endpoints in a phase III trial of Chinese patients with advanced triple-negative breast cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729258</guid>
      <pubDate>Fri, 27 Feb 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729258-systimmunes-iza-bren-hits-phase-iii-breast-cancer-goals-in-china</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/breast-cancer-wireframe.webp?t=1706887459" type="image/jpeg" medium="image" fileSize="349651">
        <media:title type="plain">Cancer tumor in breast illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>FDA approves CSPC’s IND for SYH-2082 for weight management</title>
      <description>
        <![CDATA[CSPC Pharmaceutical Group Ltd. has obtained IND approval from the FDA for SYH-2082 injection, a GLP-1/GIP receptor dual-biased agonist polypeptide long-acting injection for weight management for individuals with obesity or overweight and at least one weight-related comorbidity.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728886</guid>
      <pubDate>Mon, 16 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728886-fda-approves-cspcs-ind-for-syh-2082-for-weight-management</link>
    </item>
    <item>
      <title>Viking to push oral GLP-1/GIP drug into phase III obesity trial </title>
      <description>
        <![CDATA[Viking Therapeutics Inc. said after-market hours Feb. 11 that it plans to advance its oral dual GLP-1/GIP receptor, VK-2735, into a phase III trial for obesity in the third quarter of 2026. VK-2735 is a novel dual glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide (GLP-1/GIP) receptor agonist.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728847</guid>
      <pubDate>Thu, 12 Feb 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728847-viking-to-push-oral-glp-1-gip-drug-into-phase-iii-obesity-trial</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Pills_generic.webp?t=1588352752" type="image/png" medium="image" fileSize="311815">
        <media:title type="plain">Pills and bottle</media:title>
      </media:content>
    </item>
    <item>
      <title>Precision Biosciences’ PBGENE-DMD cleared to enter clinic</title>
      <description>
        <![CDATA[Precision Biosciences Inc. has received FDA clearance of its IND application enabling clinical trial site activation for a phase I/II trial (FUNCTION-DMD) of PBGENE-DMD for the treatment of ambulatory patients with Duchenne muscular dystrophy (DMD). The first site in the U.S. will be activated in the first half of this year.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728787</guid>
      <pubDate>Wed, 11 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728787-precision-biosciences-pbgene-dmd-cleared-to-enter-clinic</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/DNA-human-body-genetics.webp?t=1727276897" type="image/jpeg" medium="image" fileSize="144422">
        <media:title type="plain">Illustration of DNA composing the human body</media:title>
      </media:content>
    </item>
  </channel>
</rss>
